NIH public-private partnership to advance early interventions for schizophrenia

The National Institutes of Health (NIH) is launching a new public-private partnership to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia. Part of the Accelerating Medicines Partnership (AMP), AMP Schizophrenia (SCZ) brings together NIH, the U.S. Food and Drug Administration and multiple non-profit and private organizations. These partners will work toward the shared mission of discovering promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other outcomes and define targets for treatment development.

The National Institute of Mental Health (NIMH) expects to contribute $82.5 million over five years, pending availability of funds. NIMH is currently supporting three research projects as part of the AMP SCZ initiative.